AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25452446 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricoxib 400 mg once per day with docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days
Number of subjects: 72
Study 25452446 — intervention group
Group type: COMPARATOR
Intervention: Placebo with docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days
Number of subjects: 72
Study 23186975 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily (OD)
Number of subjects: 0
Study 23186975 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg OD
Number of subjects: 0
Study 23186975 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 0
Study 22162646 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial six-month lifestyle intervention for obesity
Number of subjects: 110
Study 22162646 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment 3.5 years later
Number of subjects: 110
Study 22162646 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful participants (maintained losses of 5% or greater)
Number of subjects: 110
Study 22162646 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring behaviors
Number of subjects: 110
Study 17875305 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg QD
Number of subjects: 122
Study 17875305 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg QD
Number of subjects: 122
Study 17262147 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrofilling with MTA after Er;Cr:YSGG laser irradiation (2.78 microm, 4 W, 20 Hz, 70.8 J/cm(2))
Number of subjects: 22
Study 17262147 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrofilling with cyanoacrylate after Er;Cr:YSGG laser irradiation
Number of subjects: 22
Study 17262147 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrofilling with MTA without laser irradiation
Number of subjects: 22
Study 17262147 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrofilling with cyanoacrylate without laser irradiation
Number of subjects: 22
Study 17262147 — intervention group
Group type: COMPARATOR
Intervention: Positive control (not specified)
Number of subjects: 22
Study 17262147 — intervention group
Group type: COMPARATOR
Intervention: Negative control (not specified)
Number of subjects: 22
Study 12657338 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental and policy interventions for physical activity
Number of subjects: 24
Study 12657338 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental and policy interventions for fat intake
Number of subjects: 24
Study 12657338 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental and policy interventions
Number of subjects: 24
Study 11094868 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-10 (rHuIL-10) at doses of 5, 10, or 20 micrograms/kg, administered subcutaneously, once daily for 28 days
Number of subjects: 17
Study 11094868 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 9365526 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte-colony stimulating factor (rhG-CSF) administered after the first or second chemotherapy cycle
Number of subjects: 12
Study 9365526 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose chemotherapy and rhG-CSF
Number of subjects: 12
Study 9365526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 12
Study 1554036 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg daily
Number of subjects: 69
Study 1554036 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg daily
Number of subjects: 69
Study 1554036 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg daily
Number of subjects: 69
Study 1554036 — intervention group
Group type: COMPARATOR
Intervention: Plasma haloperidol levels above 12 ng/ml
Number of subjects: 69
Study 2867575 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 70
Study 2867575 — intervention group
Group type: COMPARATOR
Intervention: Sham ECT
Number of subjects: 70
Study 30992024 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for dialysis
Number of subjects: 16
Study 30992024 — intervention group
Group type: COMPARATOR
Intervention: Preparing for conservative care
Number of subjects: 16
Study 30072213 — intervention group
Group type: EXPERIMENTAL
Intervention: BKV or CMV viral loads over 10,000 copies·mL‐1
Number of subjects: 540
Study 30072213 — intervention group
Group type: EXPERIMENTAL
Intervention: BKV-CMV combined reactivation
Number of subjects: 540
Study 30072213 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV reactivation
Number of subjects: 540
Study 26278005 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended morning fasting
Number of subjects: 24
Study 25621158 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 12
Study 22298867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1500 mL of an isotonic solution per day for 6 days
Number of subjects: 137
Study 22298867 — intervention group
Group type: EXPERIMENTAL
Intervention: Home oral hydration therapy of 1500 mL/d (subgroup A1)
Number of subjects: 137
Study 22298867 — intervention group
Group type: EXPERIMENTAL
Intervention: Home oral hydration therapy of 2500 mL/d (subgroup A2)
Number of subjects: 137
Study 22298867 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancies without oligohydramnios (control group B)
Number of subjects: 137
Study 20022201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based telephone intervention
Number of subjects: 215
Study 20022201 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 215
Study 17908193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton pajamas
Number of subjects: 0
Study 17908193 — intervention group
Group type: COMPARATOR
Intervention: Polyester pajamas
Number of subjects: 0
Study 15064300 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise in normoxia (N)
Number of subjects: 9
Study 15064300 — intervention group
Group type: COMPARATOR
Intervention: Progressive exercise in hypoxia (H)
Number of subjects: 9
Study 11588406 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg)
Number of subjects: 588
Study 11588406 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 588
Study 11588406 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80 mg)
Number of subjects: 588
Study 11588406 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (150 mg)
Number of subjects: 588
Study 9718376 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin
Number of subjects: 208
Study 9718376 — intervention group
Group type: COMPARATOR
Intervention: Intravenous epoetin
Number of subjects: 208
Study 7639807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega 3 fatty acids (130 mg/kg/day)
Number of subjects: 66
Study 7639807 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (9 capsules/day)
Number of subjects: 66
Study 2619780 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphylong-pellets (formulation E)
Number of subjects: 18
Study 2619780 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (twice-daily dosage)
Number of subjects: 18
Study 849537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocusert Pilocarpine (P20)
Number of subjects: 0
Study 849537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocusert Pilocarpine (P40)
Number of subjects: 0
Study 849537 — intervention group
Group type: COMPARATOR
Intervention: Aqueous pilocarpine drops
Number of subjects: 0
Study 31809326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab followed by nab-paclitaxel and bevacizumab (AB)
Number of subjects: 0
Study 31809326 — intervention group
Group type: COMPARATOR
Intervention: Nab-paclitaxel and bevacizumab (AB) followed by ipilimumab
Number of subjects: 0
Study 30768493 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide and simethicone
Number of subjects: 120
Study 30768493 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 120
Study 28290764 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 80
Study 28290764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise
Number of subjects: 80
Study 28290764 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural exercise
Number of subjects: 80
Study 28290764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 24939678 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS-guided temporal artery biopsy (TAB)
Number of subjects: 112
Study 24939678 — intervention group
Group type: COMPARATOR
Intervention: Standard temporal artery biopsy (TAB)
Number of subjects: 112
Study 23232255 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%
Number of subjects: 88
Study 23232255 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1.0%
Number of subjects: 88
Study 21310829 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Hydrolysate Formula (PHF) for 3 months
Number of subjects: 6
Study 21310829 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Hydrolysate Formula (PHF) for 1 month starting at 3.5 months
Number of subjects: 6
Study 21310829 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Hydrolysate Formula (PHF) for 7 months
Number of subjects: 6
Study 21310829 — intervention group
Group type: COMPARATOR
Intervention: Cow Milk-Based Formula (CMF)
Number of subjects: 6
Study 19342148 — intervention group
Group type: EXPERIMENTAL
Intervention: ART restorations with cavity disinfection
Number of subjects: 90
Study 19342148 — intervention group
Group type: COMPARATOR
Intervention: ART restorations without cavity disinfection
Number of subjects: 90
Study 19342148 — intervention group
Group type: EXPERIMENTAL
Intervention: All ART restorations
Number of subjects: 90
Study 19342148 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-surface ART restorations
Number of subjects: 90
Study 19342148 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-surface ART restorations
Number of subjects: 90
Study 19342148 — intervention group
Group type: EXPERIMENTAL
Intervention: All ART restorations by gender
Number of subjects: 90
Study 15925816 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg orally once a day) and Anastrozole (1 mg orally once a day)
Number of subjects: 56
Study 15925816 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg orally once a day)
Number of subjects: 56
Study 15925816 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib and Anastrozole
Number of subjects: 56
Study 15925816 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 56
Study 15925816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 12061685 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT cholangiography (CT/+ group, n = 13)
Number of subjects: 53
Study 12061685 — intervention group
Group type: COMPARATOR
Intervention: No helical CT cholangiography (CT/- group, n = 15)
Number of subjects: 53
Study 10404575 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifidus muscle vibration (70 Hz, 0.5 mm amplitude for approximately 5 seconds)
Number of subjects: 25
Study 10404575 — intervention group
Group type: COMPARATOR
Intervention: Control group (only heard the vibrator noise)
Number of subjects: 25
Study 9002913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measures (body and knee heights)
Number of subjects: 46
Study 9002913 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of DHEAS and osteocalcin measured every three months
Number of subjects: 46
Study 9002913 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical measures (height and skeletal maturation)
Number of subjects: 46
Study 2340834 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa/bromocriptine
Number of subjects: 31
Study 2340834 — intervention group
Group type: COMPARATOR
Intervention: L-dopa alone
Number of subjects: 31
Study 6988462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tru-Cut sheathed needle
Number of subjects: 77
Study 6988462 — intervention group
Group type: COMPARATOR
Intervention: Menghini suction biopsy needle
Number of subjects: 77
Study 31746443 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPO
Number of subjects: 163
Study 31746443 — intervention group
Group type: COMPARATOR
Intervention: IMN
Number of subjects: 163
Study 31746443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 163
Study 31070845 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 13
Study 31070845 — intervention group
Group type: COMPARATOR
Intervention: Desoximetasone ointment
Number of subjects: 13
Study 27727138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online curriculum with weekly reading assignments (GROUP 1)
Number of subjects: 53
Study 27727138 — intervention group
Group type: COMPARATOR
Intervention: No access to the online curriculum (GROUP 2)
Number of subjects: 53
Study 25040299 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouth rinse
Number of subjects: 62
Study 25040299 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (VC) mouth rinse
Number of subjects: 62
Study 23589230 — intervention group
Group type: COMPARATOR
Intervention: Squatting alone (S)
Number of subjects: 6
Study 23589230 — intervention group
Group type: COMPARATOR
Intervention: Squatting + vibration (SV)
Number of subjects: 6
Study 23589230 — intervention group
Group type: COMPARATOR
Intervention: Squatting + external load (SE)
Number of subjects: 6
Study 23589230 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting + external load + vibration (SEV)
Number of subjects: 6
Study 21320366 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet (n=39)
Number of subjects: 106
Study 21320366 — intervention group
Group type: EXPERIMENTAL
Intervention: LF diet (n=43)
Number of subjects: 106
Study 21320366 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n=24)
Number of subjects: 106
Study 19944363 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sodium restriction (120mmol to 2.8g/day) plus oral furosemide (125 to 250mg bid)
Number of subjects: 173
Study 19944363 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (80mmol to 1.8g/day) plus oral furosemide (125 to 250mg bid)
Number of subjects: 173
Study 17417709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cutting scissors technique
Number of subjects: 60
Study 17417709 — intervention group
Group type: COMPARATOR
Intervention: Standard scalpel blade technique
Number of subjects: 60
Study 15470333 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 21
Study 15470333 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 21
Study 15470333 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 21
Study 11432485 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (50 mg/kg/dose, maximum 1 g, every 8 hours)
Number of subjects: 90
Study 11432485 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (200 mg/kg/dose, every 6 hours) plus Amikacin (15 mg/kg daily)
Number of subjects: 90
Study 11432485 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-positive culture
Number of subjects: 90
Study 11432485 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-negative or mixed cultures
Number of subjects: 90
Study 11432485 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid tumor group
Number of subjects: 90
Study 9712234 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG serology (Orion Diagnostica Pyloriset New EIA‐G)
Number of subjects: 794
Study 9712234 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule 14C urea breath test (UBT)
Number of subjects: 794
Study 9712234 — intervention group
Group type: COMPARATOR
Intervention: Rapid urease test (RUT)
Number of subjects: 794
Study 9712234 — intervention group
Group type: COMPARATOR
Intervention: Culture
Number of subjects: 794
Study 9712234 — intervention group
Group type: COMPARATOR
Intervention: Non-capsule UBT
Number of subjects: 794
Study 9712234 — intervention group
Group type: COMPARATOR
Intervention: Capsule UBT
Number of subjects: 794
Study 8308505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone aqueous nasal spray 100 micrograms twice daily
Number of subjects: 238
Study 8308505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone aqueous nasal spray 200 micrograms once daily
Number of subjects: 238
Study 8308505 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone aqueous nasal spray 168 micrograms twice daily
Number of subjects: 238
Study 8308505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 2658700 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 200 micrograms
Number of subjects: 7
Study 2658700 — intervention group
Group type: COMPARATOR
Intervention: Inhaled propranolol
Number of subjects: 7
Study 2658700 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 7
Study 2658700 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 7
Study 5272349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendehill rubella virus vaccine
Number of subjects: 16000
Study 31669047 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Counseling
Number of subjects: 264
Study 31669047 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study 29637645 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach-to-Recovery (RTR) + PA
Number of subjects: 76
Study 29637645 — intervention group
Group type: COMPARATOR
Intervention: RTR Control
Number of subjects: 76
Study 28364870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (o-CEE, 0.45mg/day)
Number of subjects: 0
Study 28364870 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β estradiol (t-E2, 50μg/day)
Number of subjects: 0
Study 28364870 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills and patches
Number of subjects: 0
Study 28364870 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (o-CEE, t-E2)
Number of subjects: 0
Study 28364870 — intervention group
Group type: EXPERIMENTAL
Intervention: Three years after discontinuation of study treatments
Number of subjects: 0
Study 26176878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patches
Number of subjects: 0
Study 26176878 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study 23615094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKRS)
Number of subjects: 237
Study 23615094 — intervention group
Group type: COMPARATOR
Intervention: Conservative Management (CM)
Number of subjects: 237
Study 21306826 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress (depression and stress)
Number of subjects: 231
Study 21306826 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression and stress
Number of subjects: 231
Study 21306826 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 231
Study 19544653 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic therapy plus ozone therapy
Number of subjects: 42
Study 19544653 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 42
Study 17205825 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg once per day after breakfast for 8 weeks
Number of subjects: 0
Study 17205825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Xiaoyao Decoction (XD) and Wendan Decoction (WD) one dose a day before supper for 8 weeks
Number of subjects: 0
Study 12885809 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of lymph nodes analyzed from surgical specimens
Number of subjects: 3411
Study 12885809 — intervention group
Group type: COMPARATOR
Intervention: No lymph node involvement
Number of subjects: 3411
Study 10533862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan membranes
Number of subjects: 180
Study 10533862 — intervention group
Group type: COMPARATOR
Intervention: Polymethyl-methacrylate membranes
Number of subjects: 180
Study 8739053 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture with autologous cryopreserved endometrial cells
Number of subjects: 21
Study 8739053 — intervention group
Group type: COMPARATOR
Intervention: Control (no coculture)
Number of subjects: 21
Study 1718366 — intervention group
Group type: COMPARATOR
Intervention: 2 mg Cu/d
Number of subjects: 21
Study 1718366 — intervention group
Group type: COMPARATOR
Intervention: 3 mg Cu/d
Number of subjects: 21
Study 6173204 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical constant current stimuli (20 msec, 2‐8 mA)
Number of subjects: 0
Study 6173204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical force controlled stimuli (20 msec, 0.8‐3.2 N)
Number of subjects: 0
Study 31329216 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0530 (100 mg or 125 mg daily)
Number of subjects: 159
Study 31329216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 31329216 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0530
Number of subjects: 159
Study 27106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee joint distraction
Number of subjects: 69
Study 27106926 — intervention group
Group type: COMPARATOR
Intervention: High tibial osteotomy (HTO)
Number of subjects: 69
Study 25724985 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-B vaccine
Number of subjects: 30
Study 25724985 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-B/disulfiram
Number of subjects: 30
Study 25724985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24001464 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care cardiac rehabilitation (SC-CR)
Number of subjects: 208
Study 24001464 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (H-CR)
Number of subjects: 208
Study 21251283 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF)
Number of subjects: 17
Study 21251283 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (HF)
Number of subjects: 17
Study 19476398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 0